Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study
Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study have?
Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study has 4 citations in the OpenAlex counts ScholarIQ stores.
When was Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study published?
Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study has 2025 year in the ScholarIQ index.
What is the open-access status of Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study?
Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study has closed oa status in the ScholarIQ index.
What is the DOI of Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study?
The DOI for Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study is on the source record.
What is the PMID of Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study?
The PMID for Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study is on the source record.
What is the OpenAlex record for Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study?
The OpenAlex for Risk of urinary tract infections associated with SGLT2 inhibitor use in patients with RA: a target trial emulation study is on the source record.